another run up, page-6

The annual report did highlight some interesting points including the following.

"In China the negotiations have been lengthy and complex since the P.R.C is a highly regulated society generally, and numerous government approvals are required, particularly in heavily regulated sectors such as health and hospitality which have been identified as
primary markets."

"The Board is very confident that it will be in a position shortly to announce the finalisation of a number of contracts that will establish production and marketing for products deploying Microgenix technology in the P.R.C and a very cost effective manufacturing supply
source for other markets."

They are also developing the product to be effective against bird flu and manufacturing will take place in China which will reduce cost. Overall, the product has good potential.

Ace..